论文部分内容阅读
目的利用荟萃分析的方法对联合应用依达拉奉及红花黄色素注射液治疗急性脑梗死的临床疗效和用药安全性进行评析。方法在多个数据库中检索于1989年至2012年公开发表的关于依达拉奉联合红花黄色素注射液治疗急性脑梗死的临床随机对照试验的文献,从中筛选符合纳入标准的文献,提取数据后,采用ReviewManager5.1.7软件统计并分析相关数据。结果共有6项研究符合纳入标准。相对于对照组,依达拉奉联合红花黄色素注射液治疗急性脑梗死的神经功能缺损临床疗效比值比(OR)合并值为3.52(95%CI为2.20~5.62)。神经功能缺损评分疗效加权均数差(WMD)合并值为-4.39(95%CI为-6.64~-2.15)。结论荟萃分析的结果提示,依达拉奉联合红花黄色素注射液治疗急性脑梗死安全、有效,可用于改善患者的神经功能缺损及临床症状。
Objective To evaluate the clinical efficacy and safety of combination therapy of edaravone and safflower yellow in the treatment of acute cerebral infarction by meta-analysis. Methods A literature review of randomized controlled trials of edaravone combined with safflower yellow injections for the treatment of acute cerebral infarction from 1989 to 2012 was searched in several databases and the relevant literature was screened out for inclusion in the literature to extract data After using ReviewManager5.1.7 software statistics and analysis of relevant data. Results A total of six studies met the inclusion criteria. Compared with the control group, edaravone combined with safflower yellow injection for the treatment of acute cerebral infarction neurological deficit clinical effect odds ratio (OR) was 3.52 (95% CI 2.20 ~ 5.62). Neurological impairment score The weighted mean difference (WMD) combined value was -4.39 (95% CI -6.64 ~ -2.15). Conclusions The results of meta-analysis suggest that edaravone combined with safflower yellow injection is safe and effective in the treatment of acute cerebral infarction and can be used to improve the neurological deficits and clinical symptoms of patients.